Trending Now
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology Times
Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology Times
Q&A: Frank Holz shares how innovation showcased at EURETINA brings hope for patients with GA | Ophthalmology Times
Breaking News
Surgical innovation in dry eye disease: Salivary gland transplant
Next-generation IOLs advance complex cataract care
OCT changes with low-level red light therapy for myopia in children
Alcon presenting at APACRS 2025
Breaking News
Popular Now
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has granted…
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology Times
(Image Credit: AdobeStock/artacet) The US Food and Drug Administration (FDA) has granted…
Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology Times
(Image credit: AdobeStock/J Bettencourt) In conversation with Sydney M. Crago, Managing Editor…
Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial | Ophthalmology Times
Image credit: AdobeStock/MrAshi On September 4, 2025, Merck and EyeBio announced that…
Collaborate With Us
Editor Choice
Anniversary of the spectral OCT prototype: 25 years young and growing | Ophthalmology Times
A recent conference celebrated the creation of the first prototype of the…
Researchers assess atropine and cyclopentolate for detecting premyopia in young children | Ophthalmology Times
(Image Credit: AdobeStock) A comparison of 2 cycloplegic agents, atropine and cyclopentolate,…
Kala Bio’s CHASE trial misses primary endpoint, KPI-012 development discontinued | Ophthalmology Times
(Image Credit: AdobeStock) Kala Bio announced that CHASE (NCT05727878), its phase 2b…
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitors | Ophthalmology Times
Photo of Mark Gillies at the 2025 EURETINA meeting Mark Gillies, MD,…
The Netherlands: Lupin strengthens ophthalmology business with acquisition of VISUfarma from GHO Capital
\n European specialist investor GHO Capital Partners has announced the sale of…
Q&A: Harvey Uy on the power of digital images and records | Ophthalmology Times
Photo of Harvey Uy, MD, DPBO, FVRSP, at the 2025 EURETINA meeting…
Q&A: Prem S. Subramanian, MD, PhD, on neuro-ophthalmic insights at EyeCon 2025 | Ophthalmology Times
Prem S. Subramanian, MD, PhD, emphasized the importance of pattern recognition in…
Q&A: Marion Munk discusses the phase 2a BETTER study | Ophthalmology Times
Photo of Marion Munk at EURETINA 2025 In her conversation with the…
EyeCon 2025: Adopting an interventional glaucoma mindset with Oluwatosin U. Smith, MD | Ophthalmology Times
At this year’s EyeCon meeting, Oluwatosin U. Smith, MD, of the Glaucoma…
Worth Reading
Meeting expectations with evolving technology
Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Next-generation IOLs advance complex cataract care
Subscribe Now
Enter your email address below and subscribe to our newsletter